Daily Low-level Red Light and 0.01% Low-dose Atropine for Myopia Prevention
NCT ID: NCT06727019
Last Updated: 2024-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
138 participants
INTERVENTIONAL
2023-04-10
2023-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
red-light
In the low-level red-light (LLRL) group, the children used LLRL irradiation twice a day for 3-minute sessions, ensuring a gap of over 4 h between each use
low-level red-light
650-nm low-level red-light
atropine
participants in the atropine group used 0.01% low-dose atropine eye drops once each night
Atropine (0.01%)
Atropine eye drops at concentration of 0.01%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
low-level red-light
650-nm low-level red-light
Atropine (0.01%)
Atropine eye drops at concentration of 0.01%
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
3\. Had a record of cycloplegia SER at least 6 months before this study, and SER changed -0.5D compared with the last measurement or had a family history of high myopia.
4\. Corneal astigmatism ≤ 1.25D. 5. Interocular refraction discrepancy ≤ 1.5D. 6. No allergy history of cycloplegia drugs. 7. Willingness to participate in the study and signed informed consent.
Exclusion Criteria
3\. Children currently using other myopia interventions other than LDA or LLRL. 4. Children with systemic and immune disorders, such as albinism, psoriasis, nephrotic syndrome, systemic lupus erythematosus, and diabetes 5. Individuals with conditions like Tourette's syndrome or epilepsy.
7 Years
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Tongren Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
cao kai
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Liya Qiao, PhD
Role: PRINCIPAL_INVESTIGATOR
Beijing Tongren Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Tongren Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BeijingTH2023qiao
Identifier Type: -
Identifier Source: org_study_id